Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine Monotherapy for Typical Absence Seizures in Children
NCT01431976Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of lamotrigine in Typical absence seizure (TAS), sponsored by GSK. Primary endpoint: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase. Started Sep 2011; status: completed.
02
Drugs
lamotrigine
03
Conditions
Typical absence seizure (TAS)
Beyond the preview
Go deeper on NCT01431976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431976.